Yuconor International: Deeply Engaged in Pain Management and Health Care Services, Poised to Benefit from Growth Opportunities in Hong Kong's Musculoskeletal Health Market

In recent years, Hong Kong's demographic structure has continued to shift, with musculoskeletal-related health issues becoming increasingly common among middle-aged and older populations. Market demand for non-invasive pain management and function maintenance health services has steadily risen, driving continuous expansion of the local health and wellness sector. At the same time, as public health awareness upgrades from "disease treatment" to "full-cycle health management," the non-invasive, non-pharmacological pain management and healthcare services sector has gradually moved from a niche market into the mainstream spotlight, attracting more capital attention and positioning. Recently, Hong Kong healthcare service provider Yuconor International, which has filed with the Hong Kong Stock Exchange, operates under the core brand "Regeneration" and positions itself in non-surgical, non-invasive, non-pharmacological pain management and function enhancement services. It is a relatively mature market participant with a long operating history in this sector. This also makes it the most tangible regional market sample for observing the operational logic, competitive barriers, and growth potential of this niche sector. **Continuous Profitability, High Financial Quality, and High Stickiness Highlight Strong Fundamentals** It is understood that since its establishment in 2007, Yuconor International has been deeply engaged in the pain management and health services field for over 18 years and has accumulated a certain reputation in Hong Kong under the "Regeneration" brand. It is understood that Hong Kong's pain management market is relatively fragmented overall. Based on 2025 revenue, Yuconor holds approximately 3.8% market share among Hong Kong private pain management solution providers. Its industry position combined with steadily growing performance undoubtedly serves as a positive factor for Yuconor International's Hong Kong IPO. According to the prospectus, Yuconor's core technology is the "RDS+" pain management and function enhancement method, which integrates traditional Chinese medicine wisdom with international energy therapy equipment technology. The company combines TCM meridian and qi-blood circulation theory with internationally certified energy therapy devices procured from Germany, Korea, Japan, and other countries, executed by a team of registered TCM practitioners, senior function enhancement consultants with physiotherapy backgrounds, and standardized trained therapists. During the track record period, therapists completed over 364,000 treatment sessions in aggregate. As the company's treatments and therapies are non-surgical, non-invasive, and non-pharmacological, they can effectively avoid the pain, discomfort, skin or tissue damage, and related risks associated with traditional treatment methods. Its services cover diverse downstream demand scenarios, including chronic musculoskeletal pain relief, sports injury rehabilitation, sub-health function conditioning, weight management, and daily health maintenance. Its core customer base comprises middle-to-high income working professionals, middle-aged and elderly groups, and sports-active populations. From a financial performance perspective, during the fiscal years 2024-2026, the company achieved total revenue of approximately HK$320 million, HK$312 million, and HK$368 million, respectively, representing a three-year compound annual growth rate of approximately 7.3%. On the profitability side, the company achieved positive profitability for three consecutive years, with fiscal year 2026 growing 11.5% year-over-year to HK$37.8 million. Thereafter, with new store operations and scale release, the company's profitability is expected to continue climbing. From a business structure perspective, Yuconor's main operations cover pain management and body function enhancement services, as well as sales of topical and dietary supplement products, forming part of the healthcare and elderly care service industry. The company's business is highly focused on the service side, with pain management and function enhancement services revenue consistently accounting for over 84% of total revenue, serving as the core revenue source; topical products and dietary supplements serve as supplements to the service system. From a cash flow perspective, Yuconor's business fundamentals remain robust: net cash generated from operating activities for fiscal years 2024 to 2026 was approximately HK$74.14 million, HK$85.80 million, and HK$117.2 million, respectively, with year-end bank balances and cash increasing from approximately HK$67.41 million to approximately HK$96.59 million, supporting the company's stable expansion. **Rising Function Health Needs Among Middle-Aged and Older Populations Open Up Long-Term Growth Ceiling** As Hong Kong's demographic structure continues to shift, the middle-aged and older population is steadily expanding. According to an Ipsos report, Hong Kong's population aged 40 and above has grown from approximately 4.4 million in 2020 to approximately 4.78 million in 2025. This trend drives continuously rising demand for musculoskeletal function maintenance and pain management-related health services, promoting diversified development of the health services market. During the same period, Hong Kong's pain management solutions services market size is projected to expand from approximately HK$10.15 billion in 2020 to approximately HK$19.728 billion by 2030 (forecast). Among this, the number of chronic musculoskeletal pain patients increases by 70,000 to 120,000 new patients annually, and the population aged 40 and above is expected to grow to 3.35 million by 2030. Meanwhile, Hong Kong's per capita healthcare expenditure is projected to grow from approximately HK$16,249.1 to HK$19,728.7 over the same period, representing a compound annual growth rate of 4%, indicating that demand in the pain management sector is on a continuously expanding trajectory. The continuously expanding pain management market undoubtedly creates a solid foundation for Yuconor International's business expansion. According to the prospectus, in terms of services, the company leverages advanced energy therapy equipment to address various pain and sub-health conditions. Relying on three core operating service centers located in prime areas of Hong Kong, the company targets middle-to-high income groups in Hong Kong Island and Kowloon, deeply integrating TCM meridian theory with modern energy therapy technology to create a differentiated service product system, and has initiated a new store expansion plan. From a regional layout perspective, the company's service centers are all located in commercial buildings in core business districts such as Tsim Sha Tsui, Causeway Bay, and Sha Tin. Among these, the Causeway Bay service center has been expanded to 17,130 square feet, with treatment rooms increased from 17 to 48, and the Tsim Sha Tsui service center has been expanded to 18,579 square feet, with treatment rooms increased from 30 to 60. The balanced regional layout reduces the operational risk of a single store, while the expansion of service capacity directly drives overall growth. In fiscal year 2026, the company's total customer count grew to 11,200, with total revenue growing 17.8% year-over-year. Moreover, the mid-to-high average customer spending primarily stems from the rigid demand nature of the services chronic pain requires long-term management, and the company's non-pharmacological, non-invasive solutions have no recovery period, making them suitable for high-frequency consumption by middle-aged, elderly, and sub-health populations. This high customer stickiness also constitutes Yuconor's genuine moat. It is worth noting that, unlike some non-hospital healthcare service providers in the industry that pursue comprehensive diversified expansion, Yuconor International chooses to concentrate its core resources on the pain management and function services sector, forming a light-asset service business model with minimal risk and strong resilience. Against the macroeconomic backdrop of cautious consumer spending and intensifying Greater Bay Area competition facing Hong Kong's health and wellness industry, Yuconor focuses on the non-invasive pain management niche sector. Deep cultivation in a vertical domain allows the company to avoid the heavy-asset trial-and-error costs of diversified businesses, and to lock in high-frequency rigid demand from mid-to-high-end customer groups with a non-pharmacological, non-surgical service model, forming a profitability resilience distinct from comprehensive medical platforms stable revenue, sustained positive profitability, and healthy cash flow, in sharp contrast to peers bearing losses and asset impairment pressures from diversified expansion, which also indirectly confirms the quality of the company's fundamentals. Overall, Yuconor International's business model precisely aligns with the growing demand for non-pharmacological pain management under health consumption upgrading. Its differentiated positioning integrating TCM theory with modern technology, standardized service operation system, and relatively mature customer base constitute its core competitive barriers. As new stores ramp up capacity and brand-building investments gradually materialize, its subsequent growth momentum is ample, and its business development dynamics warrant long-term optimism.